Alvotech Shares Plunge to New 52-Week Low of $4.81

Alvotech, a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 4.81 on November 3, 2025. This significant drop highlights the company's ongoing struggles, as it has experienced a steep decline of 65.21% over the past year, contrasting sharply with the S&P 500's performance of 19.89% during the same period. The company's market capitalization stands at USD 2,463 million, with a price-to-earnings (P/E) ratio of 33.00. However, Alvotech's financial metrics reveal challenges, including a negative book value of -14.21 and a return on equity of -36.55%. The company's ability to manage its debt is also concerning, as indicated by a poor EBIT to interest ratio of -7.56. Despite a reported annual growth rate of 142.90% in net sales and 48.15% in operating profit over the last five years, these figures have not translated into positive stock performance. Alvotech's stock has generated a return of -41.06% in the past year, further emphasizing its underperformance relative to broader market indices.